Study guide
26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis
Philippine Physician Licensure Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: PLE Structure, Eligibility & Study Strategy
1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan
2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle
2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction
3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems
3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments
4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems
4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation
5 Chapter 5: Physiology IV: Neurophysiology & Special Senses
5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses
6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death
6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death
7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning
7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws
8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics
8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics
9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics
9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock
10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection
10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology
11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology
11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura
12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology
12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors
13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry
13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism
14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry
14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure
15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back
15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes
16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin
16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands
17 Chapter 17: Anatomy III: Head, Neck & Histology
17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology
18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections
18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis
19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections
19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning
20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections
20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases
21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections
21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis
22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding
22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage
23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems
23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception
24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception
24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria
25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues
25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents
26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections
26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections
27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders
27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning
28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders
28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child
29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider
29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036
30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine
30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine
31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer
31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health
32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics
32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections
33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics
33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy
34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics
34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis
35 Chapter 35: Surgery I: Basic Surgical Principles
35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety
36 Chapter 36: Surgery II: Abdomen, Breast & Hernia
36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma
37 Chapter 37: Surgery III: Surgical Specialties
37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)
38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine
38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome
39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine
39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS
40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry
40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)
26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis
Key Takeaways Explain This Topic AI
Unang Yakap (EINC) has four time-bound steps: immediate thorough drying, early skin-to-skin contact, properly timed cord clamping (1 to 3 minutes) and non-separation for breastfeeding.
In neonatal resuscitation, effective ventilation is the priority; compressions start only if the heart rate stays below 60 bpm after 30 seconds of ventilation that moves the chest.
Jaundice in the first 24 hours is always pathologic; ABO incompatibility, Rh disease, G6PD deficiency and sepsis are leading causes.
Expanded newborn screening (RA 9288) by heel prick after 24 hours of life screens for 29 disorders, including congenital hypothyroidism, CAH, G6PD deficiency, galactosemia and PKU.
Neonatal hypoglycemia is common in infants of diabetic mothers, preterm and small-for-gestational-age infants; feed early and treat symptomatic or persistent low glucose with IV dextrose.
Last updated: October 2026
Why this area matters
The TOS newborn competencies are to:
assess a normal newborn and its physiologic and anatomic variants;
arrive at a diagnosis in common newborn disorders such as respiratory distress syndrome and metabolic problems;
apply well-baby and preventive care.
Neonatal deaths make up a large share of under-five deaths in the Philippines. Most of them come from prematurity, birth asphyxia and infection. The DOH Essential Intrapartum and Newborn Care protocol, newborn screening and kangaroo mother care target exactly these causes.
The normal newborn and its variants
Normal vital signs and measurements:
- heart rate 120 to 160 bpm;
- respiratory rate 40 to 60 per minute;
- temperature 36.5 to 37.5°C;
term birth weight 2,500 to 4,000 g.
Gestational age is estimated by the Ballard score, which uses neuromuscular and physical maturity.
Normal variants that need only reassurance:
Mongolian spots: blue-gray patches over the sacrum, very common in Filipino infants. Document them so they are not mistaken for bruises.
Erythema toxicum: red macules with yellow-white papules in the first days; eosinophils on smear.
Milia , and Epstein pearls on the palate.
Acrocyanosis in the first days.
Physiologic breast enlargement and pseudomenses (vaginal withdrawal bleeding from maternal estrogen).
Caput succedaneum: scalp edema that crosses suture lines and resolves in days.
Cephalohematoma: subperiosteal bleed limited by sutures . It resolves in weeks and may worsen jaundice.
Findings that need attention:
- subgaleal hemorrhage : a fluctuant swelling that crosses sutures and can cause shock;
- a single umbilical artery (associated with renal anomalies);
- an absent red reflex (cataract or retinoblastoma);
- hip instability (Ortolani and Barlow tests);
- ambiguous genitalia;
- central cyanosis ;
- bilious vomiting;
delayed passage of meconium (beyond 48 hours).
Essential Intrapartum and Newborn Care (EINC): The 'Unang Yakap' Protocol
Promulgated under Department of Health (DOH) Administrative Order No. 2009-0025, the Essential Intrapartum and Newborn Care (EINC) guideline—popularly designated as Unang Yakap (First Embrace) —establishes an evidence-based bundle of four core sequential, time-critical practices designed to reduce preventable neonatal mortality. Disrupting this sequence increases risks of neonatal hypothermia, sepsis, intraventricular hemorrhage, and breastfeeding failure.
The Four Core Sequential Steps
Immediate and Thorough Drying (First 30 Seconds):
Using a clean, dry cloth or towel, the clinician immediately dries the infant thoroughly starting with the face, eyes, head, front, back, arms, and legs.
Rationale: Prevents rapid evaporative heat loss (the primary mechanism of neonatal hypothermia) and provides tactile stimulation to initiate spontaneous respiration.
Critical Practice: The vernix caseosa must not be wiped off, as it serves as a natural protective barrier against microbial invasion and preserves skin hydration.
Wet towels must be immediately removed and replaced with a clean, dry cover.
Early Skin-to-Skin Contact (Uninterrupted Until the First Full Breastfeed):
The unclothed, dried infant is placed prone directly on the mother's bare chest or abdomen.
The infant's back is covered with a clean, warm blanket and a knitted cap or bonnet is placed on the head.
Rationale: Provides optimal thermal stability (maternal thoracic skin temperature dynamically warms the hypothermic infant), colonizes the neonate with benign maternal skin flora rather than hospital pathogens, stabilizes cardiac rhythm and blood glucose, and promotes maternal-infant bonding through endogenous oxytocin surge.
Appropriately Timed Cord Clamping (1 to 3 Minutes):
The umbilical cord is clamped and cut only after umbilical arterial pulsations have completely ceased, typically between 1 and 3 minutes post-delivery (or up to 3 minutes in vigorous infants).
Two sterile clamps or ties are applied: the first at 2 cm from the umbilical base and the second at 5 cm from the base, with the cord severed between them using sterile scissors.
Rationale: Facilitates physiologic placental transfusion, transferring 80 to 100 mL of blood into the neonatal circulation. This increases neonatal blood volume by 30%, elevates hemoglobin and ferritin stores to prevent infant anemia through 6 months of age, and significantly reduces the incidence of intraventricular hemorrhage and necrotizing enterocolitis in preterm neonates.
Contraindicated Practice: Milking or stripping the cord toward the infant is avoided due to risks of hyperviscosity and polycythemia.
Early Initiation of Breastfeeding within the First Hour:
The clinician observes for developmental feeding readiness cues: rooting, mouth opening, licking, moving the head from side to side, and hand-to-mouth movements (typically emerging 20 to 60 minutes after birth).
The mother is assisted with latch-on and positioning (chin touching breast, mouth wide open, lower lip turned outward, more areola visible above the upper lip).
Rationale: Ensures delivery of colostrum—rich in secretory Immunoglobulin A (sIgA), lactoferrin, and white blood cells—which lines the neonatal gut mucosa to prevent bacterial translocation, provides early calories to prevent hypoglycemia, and accelerates meconium passage to reduce hyperbilirubinemia.
Obsolete and Harmful Practices Prohibited under EINC
Outdated Practice Modern EINC Consensus & Harmful Consequence
Routine tracheal or oropharyngeal suctioning Prohibited in vigorous infants; induces reflex bradycardia, laryngeal spasm, and mucosal trauma. Suction only if the airway is visibly obstructed by secretions.
Early bathing within the first 24 hours Delayed for at least 6 hours (preferably 24 hours); premature bathing triggers severe hypothermia, pulmonary hypertension, and removes protective vernix.
Immediate separation for anthropometry Footprinting, weighing, length measurement, Vitamin K, and eye prophylaxis are delayed until after the first full breastfeed.
Vigorous tactile slapping of feet or buttocks Prohibited; gentle rubbing of the back or flicking the soles provides safe, effective stimulation.
Routine administration of prelacteal feeds Strictly forbidden under Executive Order No. 51 (Milk Code); glucose water or formula alters gut microbiome and increases sepsis risk.
APGAR Score: Objective Assessment of Transition
Devised by Dr. Virginia Apgar in 1952, the APGAR score provides a standardized, rapid evaluation of the neonate's physiologic transition from intrauterine to extrauterine life. It is routinely recorded at 1 minute and 5 minutes after birth. If the 5-minute score is below 7, evaluation continues every 5 minutes up to 20 minutes.
The APGAR Scoring Grid (0 to 10 Points)
Parameter 0 Points 1 Point 2 Points
A ppearance (Color) Completely blue or pale Acrocyanosis (body pink, extremities blue) Completely pink (no cyanosis)
P ulse (Heart Rate) Absent (no heartbeat) < 100 beats per minute ≥ 100 \ge 100 ≥ 100 beats per minute
G rimace (Reflex Irritability) Flaccid; no response to stimulation Grimace or weak response Vigorous cry, cough, or sneeze
A ctivity (Muscle Tone) Limp; flaccid extremities Some flexion of extremities Active motion; well-flexed extremities
R espiration (Breathing Effort) Absent (apneic) Slow, irregular, or gasping effort Vigorous cry; regular breathing
Clinical Interpretation and Board Traps
Score 7 to 10: Reassuring, normal adaptation; routine post-delivery care.
Score 4 to 6: Moderately abnormal; indicates physiologic depression requiring thermal support, airway clearing, and tactile stimulation or assisted ventilation.
Score 0 to 3: Severely depressed; mandates immediate advanced neonatal resuscitation.
Critical Board Exam Rule: Resuscitation must never be delayed to compute the 1-minute APGAR score. Resuscitation steps under the AAP/AHA Neonatal Resuscitation Program (NRP) are governed by immediate real-time assessments of respirations and heart rate, not by waiting for a formal APGAR calculation.
Neonatal Resuscitation Program (NRP)
Approximately 10% of newborns require some assistance to begin breathing, and 1% require intensive resuscitation. The Neonatal Resuscitation Program (NRP) follows a strict algorithmic timeline structured in 30-second decision-action cycles.
Step 1: Initial Assessment at Delivery
Upon emergence, ask three rapid screening questions:
Is the infant term ?
Does the infant have good muscle tone ?
Is the infant breathing or crying ?
If the answer is YES to all three: the infant stays with the mother for routine EINC care. If the answer is NO to any question: move the infant immediately to a radiant warmer for initial resuscitation steps.
Step 2: Initial Resuscitation Steps (0 to 30 Seconds)
Provide Warmth: Position the infant under a preheated radiant warmer; leave unclothed for visualization.
Position Airway: Place the head and neck in the neutral or slightly extended 'sniffing' position. Avoid hyperextension or flexion, which obstructs the airway.
Clear Secretions (PRN): Suction the mouth first, then the nose ('M before N') with a bulb syringe only if secretions are copious or obstructing the airway.
Dry and Stimulate: Dry the infant and discard wet linens. Provide tactile stimulation by gently rubbing the back or flicking the soles of the feet.
Step 3: Positive Pressure Ventilation (PPV) (30 to 60 Seconds)
Reassess respirations and heart rate (auscultate precordium for 6 seconds and multiply by 10):
Indications for PPV: Apnea, gasping respirations, or heart rate < 100 beats per minute .
Equipment & Gas Blend: Use a flow-inflating bag, self-inflating bag, or T-piece resuscitator. For infants ≥ 35 \ge 35 ≥ 35 weeks gestation, initiate PPV with room air (21% O2) . For preterm infants < 35 < 35 < 35 weeks, initiate with 21% to 30% O2 to prevent oxidative retinal and pulmonary toxicity.
Rate: 40 to 60 breaths per minute (cadence: Breathe, two, three; Breathe, two, three ).
Peak Inspiratory Pressure: Initial PIP of 20 to 25 cmH2O; target PEEP of 5 cmH2O.
Step 4: Ventilation Corrective Steps (The MR. SOPA Mnemonic)
If heart rate is not increasing and the chest is not moving after 15 seconds of PPV, execute the MR. SOPA algorithm sequentially:
Step Corrective Action Clinical Procedure
M Mask Adjustment Reapply the mask to achieve an airtight facial seal; use the two-hand E-C technique.
R Reposition Airway Adjust head position to the neutral 'sniffing' position.
Check Attempt PPV If chest still does not move, proceed to next steps.
S Suction Mouth and Nose Clear thick secretions or meconium using a bulb syringe or suction catheter (80-100 mmHg).
O Open Mouth Open the infant's mouth slightly and lift the jaw forward.
Check Attempt PPV If chest still does not move, proceed to pressure step.
P Pressure Increase Increase PIP in increments of 5 cmH2O (maximum 30-40 cmH2O) until visible chest rise occurs.
Check Attempt PPV If chest still does not move, secure definitive airway.
A Alternative Airway Insert an endotracheal tube (ETT) or laryngeal mask airway (LMA).
Step 5: Chest Compressions
Indication: Heart rate remains < 60 beats per minute despite at least 30 seconds of effective PPV that moves the chest (ideally via an alternative airway).
Technique: Two-thumb encircling-hands technique on the lower third of the sternum (between the xiphoid process and intermammary line). Compress the chest by one-third of its anteroposterior diameter.
Ratio & Cadence: 3:1 compression-to-ventilation ratio (3 compressions followed by 1 breath). This provides 90 compressions and 30 breaths (120 events) per minute.
Oxygen Concentration: Increase supplemental oxygen to 100% FiO2 whenever chest compressions are initiated.
Step 6: Epinephrine Administration
Indication: Heart rate remains < 60 beats per minute despite 60 seconds of coordinated chest compressions and 100% PPV.
Concentration: 1:10,000 (0.1 mg/mL).
Route & Dosage:
Intravenous/Intraosseous (Preferred): Administer 0.02 mg/kg (equivalent to 0.2 mL/kg of 1:10,000) via an umbilical venous catheter (UVC), followed by a 3 mL normal saline flush.
Endotracheal Route (Temporary): 0.05 to 0.10 mg/kg (0.5 to 1.0 mL/kg), while IV/IO access is being secured.
Repeat every 3 to 5 minutes if heart rate remains < 60 bpm.
Volume Expansion: If there is documented acute blood loss (placental abruption, vasa previa) or signs of shock (pallor, weak pulses, poor perfusion), administer Normal Saline (0.9% NaCl) 10 mL/kg IV over 5 to 10 minutes.
Routine newborn care and screening
Timing: after the first breastfeed and within the first hours:
- vitamin K 1 mg IM prevents vitamin K deficiency bleeding;
- eye prophylaxis (erythromycin or tetracycline ointment) prevents gonococcal ophthalmia;
hepatitis B vaccine within 24 hours and BCG .
Bathing is delayed for at least 6 hours.
Expanded newborn screening (ENBS) under the Newborn Screening Act (RA 9288, 2004) :
a heel-prick blood spot , ideally collected after 24 hours of life and before discharge;
the expanded panel covers 29 disorders : endocrine (congenital hypothyroidism, congenital adrenal hyperplasia), metabolic (PKU, galactosemia, maple syrup urine disease, homocystinuria and other amino acid, organic acid and fatty acid oxidation disorders), G6PD deficiency , hemoglobinopathies, biotinidase deficiency and cystic fibrosis;
PhilHealth's newborn care package covers the test;
positive screens are recalled urgently for confirmatory testing.
Universal newborn hearing screening under RA 9709 (2009) uses otoacoustic emissions or automated ABR before 3 months, so that hearing loss is identified and treated by 6 months.
Kangaroo mother care (continuous skin-to-skin carrying with exclusive breastfeeding) is recommended for stable low-birth-weight infants. It reduces mortality, hypothermia and infection.
Neonatal Hyperbilirubinemia: Physiologic vs. Pathologic Jaundice
Jaundice is visible when total serum bilirubin (TSB) exceeds 5.0 mg/dL (occurring in 60% of term and 80% of preterm infants). Unconjugated bilirubin is lipid-soluble, cross-reactive with neuronal membranes, and neurotoxic; conjugated bilirubin is water-soluble and excreted in bile.
Physiologic vs. Pathologic Jaundice Criteria
Diagnostic Parameter Physiologic Jaundice Pathologic Jaundice
Time of Clinical Onset After 24 hours of life (typically days 2 to 3) Within the first 24 hours of life (always pathologic)
Rate of Bilirubin Rise < 5.0 mg/dL/day < 5.0\text{ mg/dL/day} < 5.0 mg/dL/day ( < 0.2 mg/dL/hour < 0.2\text{ mg/dL/hour} < 0.2 mg/dL/hour ) > 5.0 mg/dL/day > 5.0\text{ mg/dL/day} > 5.0 mg/dL/day ( > 0.2 mg/dL/hour > 0.2\text{ mg/dL/hour} > 0.2 mg/dL/hour )
Peak Bilirubin Level Peaks on days 3 to 5: ≤ 12 − 15 mg/dL \le 12-15\text{ mg/dL} ≤ 12 − 15 mg/dL Exceeds the 95th percentile on the Bhutani nomogram
Duration of Jaundice Resolves by day 7 to 10 (term) or day 14 (preterm) Persists > 14 days > 14\text{ days} > 14 days in term or > 21 days > 21\text{ days} > 21 days in preterm
Conjugated (Direct) Fraction Normal: < 1.0 mg/dL < 1.0\text{ mg/dL} < 1.0 mg/dL Elevated: > 1.0 mg/dL > 1.0\text{ mg/dL} > 1.0 mg/dL (if TSB ≤ 5 \le 5 ≤ 5 ) or > 20 % > 20\% > 20% of TSB
Underlying Mechanism Immature UGT1A1, short RBC lifespan (70-90d), sterile gut Hemolysis, sepsis, metabolic defects, biliary atresia
Etiologies of Indirect (Unconjugated) Hyperbilirubinemia
ABO Incompatibility: Mother is blood group O , infant is blood group A or B . Maternal anti-A or anti-B IgG antibodies cross the placenta. Typically causes mild to moderate hemolysis with spherocytes on peripheral smear; direct Coombs test is positive or weakly positive. Can occur in the first pregnancy.
Rh Isoimmunization: Mother is Rh-negative , infant is Rh-positive . Prior sensitization (sensitizing event in an earlier pregnancy) produces maternal anti-D IgG antibodies. Causes severe hemolysis, profound anemia, hepatosplenomegaly, erythroblastosis fetalis, and hydrops fetalis. Direct Coombs test is strongly positive.
G6PD Deficiency: X-linked recessive enzymopathy common in the Philippines (screened in the Philippine Newborn Screening Program under RA 9288). Red blood cells are vulnerable to oxidative stress from infections, naphthalene (mothballs), or drugs, producing acute hemolytic crises with Heinz bodies and bite cells.
Breastfeeding vs. Breast Milk Jaundice:
Breastfeeding (Lactation Failure) Jaundice: Occurs in the first week of life due to inadequate caloric/fluid intake and infrequent feeds, leading to mild dehydration, delayed meconium passage, and increased intestinal reabsorption of bilirubin via enterohepatic circulation. Management: increase feeding frequency to 8 to 12 times per day; do not discontinue breastfeeding.
Breast Milk Jaundice: Develops in the second week of life (peaks days 5 to 15, lasts up to 3 months) in thriving, vigorous infants. Caused by high levels of beta-glucuronidase and free fatty acids in breast milk that deconjugate intestinal bilirubin and inhibit hepatic glucuronosyltransferase. Management: continue breastfeeding; reassure parents.
Phototherapy and Exchange Transfusion
Phototherapy Mechanics: Blue-green light in the 460 to 490 nm wavelength spectrum penetrates neonatal skin and converts lipophilic unconjugated bilirubin into water-soluble structural isomers ( lumirubin ) via photoisomerization. Lumirubin bypasses hepatic conjugation and is excreted directly into bile and urine. Eyes must be shielded with opaque patches to prevent retinal damage, and gonads must be covered.
Bronze Baby Syndrome: A dark, grayish-brown skin discoloration occurring when phototherapy is inadvertently applied to infants with conjugated (direct) hyperbilirubinemia, resulting from photo-induced modification of copper porphyrins.
Exchange Transfusion: Indicated when total serum bilirubin reaches critical thresholds on the Bhutani nomogram or when signs of acute bilirubin encephalopathy appear. Utilizes double-volume exchange ( 160 − 170 mL/kg 160-170\text{ mL/kg} 160 − 170 mL/kg ) through an umbilical venous catheter, removing 85% of circulating red blood cells, half the intravascular bilirubin, and circulating maternal antibodies.
Kernicterus (Chronic Bilirubin Encephalopathy): Unconjugated bilirubin crosses the blood-brain barrier and deposits preferentially in the basal ganglia (globus pallidus) , subthalamic nuclei, and auditory brainstem nuclei. Clinical sequelae include choreoathetoid cerebral palsy, upward gaze palsy (Parinaud syndrome), sensorineural hearing loss, and dental enamel hypoplasia.
Neonatal Respiratory Distress: Differential Diagnosis
Respiratory distress manifests with tachypnea (respiratory rate > 60 breaths/minute > 60\text{ breaths/minute} > 60 breaths/minute ), expiratory grunting, subcostal and intercostal retractions, nasal flaring, and central cyanosis.
Comparison of Major Neonatal Pulmonary Conditions
Disease Entity Pathophysiology & Risk Factors Clinical Features Diagnostic Chest Radiography Definitive Management
Neonatal Respiratory Distress Syndrome (NRDS / HMD) Primary deficiency of pulmonary surfactant (dipalmitoylphosphatidylcholine) synthesized by Type II pneumocytes. Leads to alveolar collapse, decreased compliance, microatelectasis, and intrapulmonary shunting. Key risks: Prematurity ( < 35 < 35 < 35 weeks), maternal diabetes (fetal hyperinsulinemia suppresses surfactant production), cesarean birth without labor. Tachypnea, cyanosis, prominent expiratory grunting (compensatory PEEP to preserve FRC), and sternal retractions within minutes after delivery. Diffuse, bilateral, symmetrical reticulogranular 'ground-glass' appearance with prominent air bronchograms and low lung volumes. Early continuous positive airway pressure (CPAP 5-6 cmH2O); intratracheal exogenous surfactant (poractant alfa, beractant); antenatal betamethasone (12 mg IM q24h x 2 doses) administered to mothers at risk of preterm delivery (24-34 weeks).
Transient Tachypnea of the Newborn (TTN / 'Wet Lung') Delayed resorption and clearance of fetal alveolar fluid via epithelial sodium channels (ENaC) and pulmonary lymphatics. Key risks: Elective cesarean delivery without prior labor (absence of labor catecholamine and thoracic squeeze surge), maternal asthma, term/near-term infants. Rapid, shallow tachypnea (60 to 120 bpm) shortly after delivery; clear lung sounds or mild crackles; infant typically active and non-toxic. Resolves within 24 to 72 hours. Pulmonary hyperinflation, prominent perihilar vascular markings ( 'sunburst' pattern ), fluid within the horizontal interlobar fissures, and flattened diaphragms. Supportive care; supplemental humidified oxygen to maintain SpO2 ≥ 95 % \ge 95\% ≥ 95% ; minimal handling; enteral feedings held if respiratory rate > 80 bpm > 80\text{ bpm} > 80 bpm . Self-limiting.
Meconium Aspiration Syndrome (MAS) Intrauterine hypoxia or postmaturity triggers fetal gasping and anal sphincter relaxation, allowing aspiration of meconium into distal airways. Causes mechanical airway obstruction (ball-valve effect), chemical pneumonitis, surfactant inactivation, and secondary persistent pulmonary hypertension of the newborn (PPHN). Key risks: Post-term infants ( > 41 > 41 > 41 weeks), small for gestational age, fetal distress. Severe early respiratory distress, barrel-shaped chest (increased AP diameter due to air trapping), coarse rhonchi and rales, meconium staining of fingernails, skin, and umbilical cord. Bilateral, asymmetric, coarse, patchy infiltrates alternating with areas of compensatory hyperinflation and atelectasis; pneumothorax in 10-20% of cases. Supportive mechanical ventilation (avoid high peak pressures); exogenous surfactant replacement; inhaled nitric oxide (iNO) for documented PPHN; empiric IV ampicillin and gentamicin. Routine intrapartum tracheal suctioning of non-vigorous meconium infants is no longer recommended under modern NRP guidelines.
Neonatal hypoglycemia and other metabolic problems
Neonatal hypoglycemia:
At risk: infants of diabetic mothers, preterm, small- or large-for-gestational-age infants, and infants who are sick, cold or stressed.
Symptoms: jitteriness, poor feeding, lethargy, apnea, hypothermia and seizures.
Thresholds: many units treat a glucose below about 45 mg/dL (2.5 mmol/L) in the first days, or higher in symptomatic infants.
Management:
- early, frequent breastfeeding , and dextrose gel where available;
- for symptomatic or persistent hypoglycemia, an IV bolus of 10% dextrose 2 mL/kg followed by an infusion;
persistent hypoglycemia beyond the first days needs evaluation for hyperinsulinism or endocrine and metabolic disease.
Hypocalcemia: early, in infants of diabetic mothers, preterm and asphyxiated infants; late, from high-phosphate feeds or hypoparathyroidism (DiGeorge syndrome). It causes jitteriness and seizures.
Inborn errors of metabolism: suspect them in a previously well neonate who deteriorates after feeding begins, with vomiting, lethargy, seizures, metabolic acidosis, hypoglycemia or hyperammonemia. ENBS finds many before symptoms appear.
Neonatal sepsis
- Feature Early-onset (under 72 hours) Late-onset (after 72 hours)
- Source Maternal genital tract (vertical) Hospital or community environment
Organisms Group B streptococcus, E. coli , Listeria Klebsiella , other Gram-negatives, S. aureus , coagulase-negative staphylococci, Candida
Risk factors Prolonged rupture of membranes, maternal fever or chorioamnionitis, GBS colonization, prematurity Prematurity, central lines, ventilation, poor hand hygiene
Empiric treatment Ampicillin plus gentamicin Based on local hospital antibiograms
Presentation: signs are nonspecific : poor feeding, temperature instability (often hypothermia ), lethargy, apnea, respiratory distress, jaundice and hypoglycemia.
Evaluation: blood culture, a CBC with ratio of immature to total neutrophils, CRP, and a lumbar puncture when indicated.
Prevention: clean delivery, hand hygiene, early breastfeeding and intrapartum GBS prophylaxis .